Physician profile
Mark A Lister
NPI 1043258353
$3,964.12
in general payments reported to CMS, 2019-2025
20 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $137 · 2021: $198 · 2022: $469 · 2023: $526 · 2024: $1,037 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,354.55 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $394.26 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $317.31 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $237.77 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.86 | 2019-2021 | |
| Alcon Vision LLC | $203.56 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| New World Medical,INC. | $201.42 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Oyster Point Pharma, INC. | $156.86 | 2022-2024 | Ryzumvi, Tyrvaya |
| Avedro INC. | $126.30 | 2019 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2023 | Syfovre |
| Abbvie INC. | $122.83 | 2024 | |
| Allergan, INC. | $89.84 | 2019 | |
| Glaukos Corporation | $83.98 | 2022-2025 | Photrexa Viscous and Photrexa |
| Ocular Therapeutix, INC. | $77.15 | 2023 | Dextenza |
| Dompe US, INC. | $64.97 | 2021-2024 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $64.84 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $53.39 | 2019-2023 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Biotissue Holdings INC. | $29.19 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.